Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads
Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.
You may also be interested in...
Proposed rule issued in March 2010 requires ‘major statement’ on a drug’s side effects in ‘a clear, conspicuous, and neutral manner’ for TV and radio ads. Bill would mandate a final rule within six months.
Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.